[Skip navigation]FDA Logo links to FDA home page
Center for Drug Evaluation and Research, U.S. Food and Drug AdministrationU.S. Food and Drug AdministrationCenter for Drug Evaluation and Research
 HHS Logo links to Department of Health and Human Services website

FDA Home Page | CDER Home Page | CDER Site Info | Contact CDER | What's New @ CDER

horizonal rule
CDER Home About CDER Drug Information Regulatory Guidance CDER Calendar Specific Audiences CDER Archives
 
Powered by Google
 

 Infliximab

Product Approval Information - Licensing Action

Proper name: Infliximab
Tradename: Remicade
Manufacturer: Centocor Inc, Malvern, PA, License #1242
Expanded Indication for Use: Inhibition of progression of structural damage in patients with rheumatoid arthritis who have had an inadequate response to methotrexate
Approval Date: 12/29/2000
Type of submission: Biologics license supplement

Approval Letter (Text), (PDF)

Label (PDF)

Last Updated: 3/5/2001

 

Back to Top     Back to Index

Updated: September 25, 2003
horizonal rule

CDER Home Page | CDER Site Info | Contact CDER | What's New @ CDER
FDA Home Page | Search FDA Site | FDA A-Z Index | Contact FDA | HHS Home Page

FDA/Center for Drug Evaluation and Research